The KEAP1-NRF2-PTGR1 axis is thus a critical determinant of therapy outcomes, and corresponding pathway aberrations provide an explanation for poor clinical outcomes observed in NSCLC [20, 21]. The gene discussed is KEAP1; the disease is non-small cell lung carcinoma.